Dr. Reddy’s Laboratories has teamed up with the BIRAC, for advisory support on clinical trials of Russia’s Sputnik V COVID-19 vaccine in India.
On October 29, 2020, Dr. Reddy’s Laboratories announced its partnership with the Biotechnology Industry Research Assistance Council (BIRAC under the Department of Biotechnology, Government of India) for the advisory support on clinical trials of Sputnik V. As per the partnership, BIRAC would allow Dr. Reddy's Laboratory to identify and use clinical trial centers of BIRAC.
In September, Dr. Reddy’s and the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, struck a partnership to conduct clinical trials of the Sputnik V vaccine and its distribution in India.
As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.
Dr. Reddy’s Laboratories has received approval from the Drugs Controller General of India (DCGI) to conduct human trials of the vaccine candidate. On Nov 15, it was reported that the first batch of Russia’s Sputnik V vaccine for COVID-19 is expected to reach Kanpur’s Ganesh Shankar Vidyarthi Medical College wherein the vaccine’s Phase 2 and Phase 3 human clinical trials will be conducted. According to the CEO of Dr. Reddy's Laboratories, Erez Israeli, the third phase of the vaccine trials will not be completed in India before March 2021. He mentioned that the vaccine would be available in the second quarter (April or May) of 2021.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.
Copied!